Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mupirocin versus fusidic acid for nasal eradication of Staphylococcus aureus in hemodialysis patients with chronic kidney disease
2008-001204-23Phase 3Active
- Sponsor
- Dra. Beatriz Sanchez Sobrino
- Start
- Jul 2008
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of mupirocin and fusidic acid in Staphylococcus aureus nasal carriage (2 arms), sponsored by Dra. Beatriz Sanchez Sobrino. Primary endpoint: Eradication rate at 48 hours after treatment completion. Started Jul 2008; status: active.
02
Drugs
mupirocinfusidic acid
03
Conditions
Staphylococcus aureus nasal carriage
Beyond the preview
Go deeper on 2008-001204-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-001204-23.